title: Impact of cancer research bureaucracy on innovation, costs, and patient care.
authors.affiliation: Dana-Farber Cancer Institute-Harvard Medical School, Boston, MA.
authors.forename: David P
authors.initials: DP
authors.lastname: Steensma
authors.forename: Hagop M
authors.initials: HM
authors.lastname: Kantarjian
mesh_terms: D035843:Biomedical Research / Q000191:economics / Q000331:legislation & jurisprudence / Q000592:standards / Q000639:trends; D002986:Clinical Trials as Topic / Q000191:economics / Q000331:legislation & jurisprudence / Q000592:standards / Q000639:trends; D003284:Contract Services; D004059:Diffusion of Innovation; D028744:Ethics Committees, Research; D033161:Government Regulation; D019983:Guideline Adherence; D017048:Health Care Costs / Q000592:standards / Q000639:trends; D006291:Health Policy; D006801:Humans; D008495:Medical Oncology / Q000191:economics / Q000331:legislation & jurisprudence / Q000592:standards / Q000639:trends; D061214:Patient Safety; D017410:Practice Guidelines as Topic; D011787:Quality of Health Care / Q000191:economics / Q000331:legislation & jurisprudence / Q000592:standards / Q000639:trends; D012109:Research Support as Topic / Q000191:economics / Q000331:legislation & jurisprudence / Q000592:standards / Q000639:trends; D057188:Workflow